Liquid biopsy of cerebrospinal fluid for less invasive and more effective characterization of brain tumors
In November 2015, Dr. Joan Seoane's group at the Vall d’Hebron Institute of Oncology (VHIO) published a study in Nature Communications proposing that the cerebrospinal fluid could be used as a liquid biopsy for the early diagnosis, prognosis, therapeutic management and tracking of brain cancer.
The identification of each and every tumor type along with each respective individual molecular makeup is critical in tackling cancer with greater precision. Moreover, the study of how the tumor complexity evolves with time is crucial for the correct treatment of cancer. To date, the analysis of brain tumors has consisted of a biopsy or surgical sampling. Such approaches suppose risk per se and do not necessarily facilitate access to a representative part of the tumor. A new technique, liquid biopsy, has been recently and successfully developed which detects a tumor's specific mutations by means of the analysis of circulating tumor cell-free DNA.
The liquid biopsy 'policing' of cancer is not only facilitating a more precise treatment selection for each individual patient, but could also help us to be steps ahead of the cancer's next move. Compared to traditional tissue biopsy, it is a much less invasive technique, and represents a significant step forward towards a better detection of cancer mutations, tracking the evolution of the disease, as well as predicting the response to therapy.
Joan Seoane’s group has discovered that the cerebrospinal fluid is highly enriched in circulating tumor DNA and allows for the characterization of brain tumors. The cerebrospinal fluid flows through the brain parenchyma and the spinal cord and can be sampled by a lumbar puncture (similar to an epidural puncture). The cerebrospinal fluid liquid biopsy opens a novel, pioneering line of research into biomarkers that enable to monitor the progress of the disease and ultimately help to evaluate the effect of treatment and drug effectiveness as the cancer progresses.